Aims Somatostatin analogues (e.g. vapreotide) are used for treatment of acromegaly, endocrine tumours and variceal bleeding. The pharmacodynamic effects of vapreotide have, however, not been documented in the gastrointestinal tract. The aim of this study was to investigate the effects of continuous vapreotide administration on gastric acidity, gallbladder contraction and hormone release. Methods Ten healthy males participated in this randomised, placebo-controlled, double-blind, crossover trial. A constant vapreotide (or placebo) infusion (1.5 mg day −1 s.c.) was given for 7 days with a portable pump. Intragastric pH was monitored on days 2 and 7. Gallbladder volume was sonographically assessed and the maximal ejection fraction was calculated. In addition basal and postprandial plasma levels of gastrin and cholecystokinin (CCK) were measured.
treatment with natural somatostatin is its short half-life Introduction and the need for intravenous application. The development of synthetic analogues has solved some of these The inhibitory effects of natural and synthetic somatostatin analogues on pituitary functions and on the gastrointestinal problems. Vapreotide is an octapeptide analogue of natural somatostatin with a half-life of 164±46 min after tract have been well documented in the last decade [1] . These compounds are used for the treatment of acroa single subcutaneous injection (N. Lahlou, unpublished results). Repetitive subcutaneous injections three times megaly [2] , various endocrine tumours [3] and upper gastrointestinal bleedings [4] . Short-term systemic applidaily are therefore needed for long-term treatment, a method poorly tolerated by patients and, with repetitive cation of somatostatin has inhibitory effects on gastric acid secretion, gallbladder contraction and other gastroinplasma peaks, not imitating a physiological hormonal state. However, during long-term treatment with octreotestinal functions [5] . One main problem in chronic tide, another somatostatin analogue, it has been noted that certain inhibitory effects are reduced after repeated gastrointestinal organ systems in the same subject at stable plateau concentrations of about 2000 pg ml −1 throughout the entire infusion period [9] . plasma concentrations has, however, not yet been carried out. Therefore, throughout the course of 1 week, we
On day 1 after overnight fasting, the subcutaneous infusion pump was fixed by use of an infusion set-up to followed the effect of vapreotide during chronic treatment on intragastric pH and gastrin, the main regulatory the left upper quadrant of the abdomen. On day 2 and day 7 of each treatment period, 24 h hormone of gastric acid production. Parallel to this, we also evaluated the effect of vapreotide on postprandial intragastric pH, gallbladder contraction and plasma concentration of hormones were measured. To assess intragallbladder contraction during chronic treatment in order to indirectly estimate the risk of promoting gallstone gastric pH, a miniature combined glass electrode for continuous monitoring of intragastric pH (Ingold, formation. Since vapreotide could play this role by inhibiting cholecystokinin (CCK), the main regulating CH-8920 Urdorf, Switzerland) was inserted transnasally in the fundus-corpus area of the stomach after calibration hormone of meal-induced gallbladder contraction [7] , we simultaneously measured it during the study. To obtain at 20°C using a commercial buffer solution, and temperature correction to 37°C. The electrode was stable plasma concentrations, vapreotide was given as a continuous subcutaneous infusion using a small portable connected to a portable data-recorder (MIC, CH-4500 Solothurn, Switzerland) with a sampling rate of one pump. Repetitive plasma concentrations of vapreotide were measured during the treatment periods to control sample every 6 s. After overnight fasting, pH monitoring started at 08.30 h. Standardised meals were given after the stable function of the pump. Growth hormone and IGF-1 were also measured to assess the known pharmacocorrect placement of the electrode (breakfast), at 14.30 h (500 ml of a liquid meal, EnsureA) and at 20.00 h logical activity of vapreotide.
(supper). The subjects were allowed to drink additional water.
Methods
Gallbladder volume was assessed by high resolution Subjects real-time sonography using a 3.5 MHz sector scanner (Aloka SSD650). The probe was first placed horizontally Ten healthy male volunteers, with a median age of 25 in the right upper quadrant of the abdomen while the years (range 23-39), having a median body weight of subject was in supine position, then the probe was rotated 83 kg (range 64-93) and a median height of 183 cm to obtain the maximal possible diameter of the gallbladder (range 178-197), were selected for this trial. None of the on the screen. The machine's software directly calculated subjects had any history of previous gastrointestinal, the gallbladder volume by the sum of the cylinder metabolic or endocrine disorders, and each had a normal method, previously described by Everson [10] . In the screening physical examination and normal laboratory basal period, as well as after liquid meal ingestion, three blood tests including serum chemistry, complete blood measurements were performed at each time point (0,15, count and an electrocardiogram. All subjects were H. 30, 60, 90 and 120 min after 500 ml EnsureA) and the pylori negative based on a negative 13 C-urea breath test mean volume was taken for further calculations. At the and no gallbladder pathology including gallstones was same time, when gallbladder sonography was performed, found by abdominal ultrasound at the screening visit. The separate venous blood samples were taken for determistudy was carried out in accordance with the recommennation of plasma gastrin and cholecystokinin. Venous dations of the Declaration of Helsinki [8] and was blood samples for GH were drawn daily in the morning approved by the Ethics Committee for Human Research during both periods of treatment. Additional IGF-1 was of the University Hospital of Basel. Written informed measured before and after each treatment period. consent was obtained from each subject.
Plasma concentrations of gastrin and CCK were determined by radioimmunoassay, as previously described Experimental design
[11]. The detection limit of the assays was 25 pg ml −1 for gastrin and 3 pmol l −1 for CCK. Plasma concenThe study was carried out as a randomised, double-blind, cross-over trial. In brief, each subject had to take part in trations of GH and IGF-1 were determined by specific radioimmunoassays with a detection limit of 0.05 mU l −1 two treatment periods with continuous subcutaneous infusion of either placebo or vapreotide (1.5 mg day −1 ) for GH and 0.8 mg l −1 for IGF-1.
Before installing the infusion pump on day 1, as well over 7 days. The two periods were separated by a washout period of at least 1 week (range 7 to 23 days).
as at 6 and 12 h later, and, in addition, in the morning of every following day, venous blood samples were drawn To achieve constant drug plasma levels, the drug was infused subcutaneously with a ChronoclipA pump, a new for determination of vapreotide plasma levels. Additional samples were taken after disconnecting the pump until infusion pump that allows delivery of 1 ml day −1 for 1 week from a reservoir. This administration maintains 48 h after stopping the infusion. The plasma concentration values was characterised for each treatment group by median pH as well as 5th, 25th, 75th and 95th percentiles and the data are presented as box Whisker plots. Basal gallbladder volumes in ml were compared using Student's t-test. For further calculations, basal gallbladder volumes were taken as 100% and postprandial changes in gallbladder volume are given as % changes (mean± s.e.mean) from basal volume. Plasma concentrations of gastrin, CCK, GH and IGF-1 are given as mean± s.e.mean.
For statistical analysis, the area under the curve (AUC) of each hormone parameter as well as the maximum and the steady state plasma concentration of vapreotide were calculated for each individual subject and experiment. For comparison of parameters between vapreotide and placebo treatment and, on the other hand, between the first and last treatment day within a treatment group, data were first tested for normal distribution by the WilkShapiro test. When normal distribution could not be rejected, data were analysed by analysis of variance (ANOVA), otherwise ANOVA was applied on ranktransformed data. In cases of significant differences, ANOVA was followed by the Duncan multi-comparison test for pair-wise comparisons. For all statistical analysis, SPSS for Windows Software was used. The level of statistical significance was P=0.05. 
Intragastric acidity
Median intragastric pH profiles over 24 h obtained during of vapreotide was measured using a radioimmunoassay placebo and vapreotide treatment are shown in Figure 1 . method adapted from Mason-Garcia [12] .
The pH-distribution-curve of vapreotide and placebo is shown in Figure 2 ; additional to the median value (50th Materials percentile), the 5th, 25th, 75th and 95th percentile of 24 h pH-metry are shown in Whisker box plots (Figure 3 ). Vapreotide acetate was provided by Debiopharm
As can be seen, with placebo similar results were obtained (CH-1000 Lausanne 9, Switzerland); EnsureA (a standard liquid test meal with 16.7% protein, 30.1% lipid and 53.2% carbohydrates) was purchased from Abbott AG (CH-6330 Cham, Switzerland). ChronoclipA, a new portable infusion pump (40 g when filled) which can deliver small amounts of a drug (1 ml day −1 ), was provided by Debiotech, CH-1000 Lausanne 9, Switzerland. For each experiment, the reservoir was filled with 10 ml of sterile infusion solution and connected through the motor unit to a set-up for subcutaneous infusion (Soft SetA).
Calculations and statistical analysis
Intragastric pH measurements were recorded every 6 s over 24 h. Median pH value was calculated for each Figure 2 pH-distribution-curve of vapreotide (~day 2, { { day 7) and placebo (, day 2, A day 7) in 10 healthy volunteers.
subject as previously described [13] . Distribution of these and 1.5 on day 7, NS). During the daytime, postprandial buffer effects were seen and during the night, typical individual variability was measured with a median pH vapreotide treatment, but this reduction was much smaller than that observed during placebo treatment. Both values slightly higher than during daytime.
However, median pH values on both day 2 and day 7 during vapreotide infusion on day 2 and day 7 were significantly ( P<0.01) higher than each of the correwere significantly ( P<0.01) higher in the vapreotide group than those measured during placebo administration sponding values in the placebo group. The maximal ejection fraction was similar on day 2 and on day 7 (day 2: median 2.6 and day 7: median 1.9; Figure 1 and Whisker box plots in Figure 3) .
(18±4% and 20±6%, respectively). During both treatment periods, gallbladder volume did not reach normal On day 7, however, the median pH in the vapreotide group was significantly lower than on day 2 ( P<0.01).
basal values within 2 h after the meal (Figure 4 ). The dose of vapreotide used in this study did not raise the median intragastric pH above 4 in any of the 10
Hormone secretion subjects (Figure 2) . Plasma hormone levels of gastrin and CCK were measured parallel to the postprandial intragastric pH and gallbladder Gallbladder volume contraction after a liquid lunch meal. There was no difference in postprandial gastrin secretion in both groups In the control period during placebo administration, basal gallbladder volumes were comparable on both days:
( Table 1) . The fasting baseline concentrations of gastrin did not 17±2 ml on day 2, respectively 15±2 ml on day 7 (Ratio 1.2; 95% CI=0.9-1.5). No significant differences differ in the placebo group comparing day 2 and day 7 (35±2 pg ml −1 , 33±2 respectively). In the group treated were found postprandially with placebo treatment between day 2 and day 7. After ingestion of 500 ml of a with vapreotide, however, the basal concentrations of gastrin were significantly higher on day 2 (40±3 pg ml −1 ; liquid meal, gallbladder volume reached its minimal residual volume in the placebo group within 60 min, as P<0.05 vs placebo and P<0.01 vs day 7) but no longer differed from the placebo group on day 7 (34±2 in the can be seen in Figure 4 . The ejection fraction at the time of maximal contraction was 63±10% on day 2 and vapreotide group). Fasting secretion of CCK did not differ between the 64±9% on day 7, respectively (NS).
During vapreotide treatment, there was a significant treatments or within each treatment between day 2 and day 7. enlargement of basal gallbladder volume to 25±3 ml (day 2, P<0.05 vs placebo) and 29±2 ml (day 7, P<0.01
Postprandial secretion of cholecystokinin was, however, slightly reduced during treatment with vapreotide vs placebo). There was no significant difference between the two latter volumes. A significant reduction of the (Table 1 ). While this difference was not significant, a similar trend could be shown on both days ( Figure 5 ). residual volume 60 min after the meal, compared with basal gallbladder volume (21±3 ml on day 2, respectively
In the control period during placebo administration, the AUC of plasma concentration of GH was 112±163, 24±3 ml on day 7) was observed in the period with 
Side effects
Some subjects complained of steatorrhoea and abdominal pain of a mild to moderate degree, but only one of them had to be treated with a spasmolytic drug for abdominal cramps, most probably due to an irritable colon (same complaints in verum and placebo phases).
Discussion
Intragastric pH was markedly elevated by vapreotide, but only at the beginning of a long term treatment, while the elevation was much lower after 1 week. The efficacy concerning gallbladder contraction, however, did not higher than in the placebo group on day 2, while there was no change after 1 week of treatment. Postprandial gastrin levels were not affected by the treatments. Postprandial cholecystokinin levels were slightly reduced while in the period during vapreotide administration it was 52±55 (P<0.01 vs placebo).
at the beginning of the vapreotide phase and after 1 week of treatment. Using a pump for continuous subcutaneous Mean baseline concentrations of IGF-1 before the administration were similar in both treatment groups: administration of vapreotide, the plasma levels of the drug were maintained at about 2000 pg ml −1 throughout 231±73 mg l −1 and 244±58 mg l −1 in the placebo and vapreotide group, respectively. During placebo treatment the entire period. The present study has shown a marked elevation of there was no change in the IGF-1 concentrations on day 7 (249±75 mg l −1 ) as compared with values before intragastric pH by the synthetic somatostatin analogue vapreotide. This effect could be demonstrated on day 2, administration. In contrast to this, IGF-1 concentrations decreased significantly ( P<0.01) to 178±46 mg l −1 but only to a much smaller extent on day 7 after continuous vapreotide infusion during 1 week, suggesting during subcutaneous administration of vapreotide. The latter value was also significantly ( P<0.01) lower than tachyphylaxis. A similar disappearance of the efficacy, with regard to intragastric pH after chronic treatment, IGF-1 concentration on day 7 in the placebo group.
has been previously demonstrated with octreotide, another somatostatin analogue, given as rapid s.c. injection Vapreotide plasma levels twice daily by Londong and coworkers [6] , but the present study was the first using continuous infusion. During the 7 days of treatment with a constant subcutaneous infusion of 1.5 mg day −1 , steady state plasma The reason for the loss of efficacy after several days of treatment with a synthetic somatostatin analogue concentration of 2062±180 pg ml −1 could be achieved.
Maximal plasma concentration was 3366±527 pg ml −1 , remains unclear. Since plasma gastrin levels were not reduced under the area under the curve 406±35 ng ml −1 h. treatment conditions, it seems that the inhibitory effect were able to suppress GH during the entire period of vapreotide infusion showing a pharmacological activity of vapreotide on intragastric pH is not mediated by suppression of gastrin, the main regulatory peptide of of the drug. No major side effects appeared in the verum period and the system was well tolerated by the volunteers. gastric acid secretion. This suggests a direct inhibition of histamine producing cells and/or parietal cells in the stomach, and this inhibition shows a tachyphylaxis.
The initial rise in basal gastrin levels on day 2 in the
